Entrar/Registro  
HOME SPANISH
 
Gaceta Médica de México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Gaceta Médica de México >Year 2013, Issue 5


Cervantes-Arriaga A, Rodríguez-Violante M, López-Ruiz M, Estrada-Bellmann I, Zuñiga-Ramírez C, Otero-Cerdeira E, Camacho-Ordoñez A, González-Latapi P, Morales-Briceño H, Martínez-Ramírez D
Profile characterization of Parkinson’s disease in Mexico: ReMePARK study
Gac Med Mex 2013; 149 (5)

Language: Español
References: 15
Page: 497-501
PDF: 77.12 Kb.


Full text




ABSTRACT

Introduction: The Mexican Registry of Parkinson´s disease (ReMePARK) is nested within a multicentric cohort aimed to describe motor, non-motor, and genetic determinants of Parkinson’s disease in Mexican patients. Material and methods: To date, clinical and demographic data from 1,083 subjects has been obtained. Here we present the demographic and clinical data of the current sample along with its comparison with international reports. Results: A total of 607 male and 476 female subjects with Parkinson’s disease were included. The mean age of the patients was 64.7 ± 12.9 years. The time from onset of symptoms to diagnosis was 2.4 ± 2.6 years. About 34% of subjects had only elementary education. Of the subjects, 54.4% were under treatment with dopamine agonists. Conclusion: Subjects with Parkinson’s disease incorporated into ReMePARK are comparable with other international registries, with the exception of the years of formal education, time to diagnosis, and the use of dopamine agonists. The characterization of the Mexican population with Parkinson’s disease will improve diagnosis and therapeutic management as well as define research efforts in this area. Finally, registry future directions are presented.


Key words: Parkinson’s disease, Mexico, Registry.


REFERENCIAS

  1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384-6.

  2. Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson’s disease: a populationbased study of US medicare beneficiaries. Neuroepidemiology. 2010; 34:143-51.

  3. Sharma M, Ioannidis JP, Aasly JO, et al. Large-scale replication and heterogeneity in Parkinson’s disease genetic loci. Neurology. 2012;79:659-67.

  4. Cervantes-Arriaga A, Rodríguez-Violante M, Zuñiga-Ramírez C, et al. Protocolo de estudio para una cohorte multicéntrica de pacientes mexicanos con enfermedad de Parkinson para evaluar los determinantes motores, no motores y genéticos sobre la progresión. Arch Neurocien (Mex). 2012;17:159-64.

  5. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745-52.

  6. Rodríguez-Violante M, Ramírez-Valadez C, Mathieu Betancour R, López- Ruiz M, Cervantes-Arriaga A, Morales-Briceño H. Características clínicas y fenotipo motor de pacientes mexicanos con enfermedad de Parkinson de tres centros de referencia de la Ciudad de México. Rev Mex Neuroci. 2011;12:288.

  7. Rodríguez-Violante M, López-Ruiz M, Cervantes-Arriaga A, Morales-Briceño H. Estudio piloto de la implementación de la escala corta de evaluación de la enfermedad de Parkinson (SPES/SCOPA) en pacientes de dos centros de referencia de la Ciudad de México. Rev Mex Neuroci. 2011;12:386.

  8. Rodríguez-Violante M, López-Ruiz Minerva, Estrada-Bellmann I, Cervantes- Arriaga A. Implementación de una evaluación corta estandarizada de la enfermedad de Parkinson. Rev Mex Neuroci. 2012;13:183-6.

  9. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-42.

  10. ELEP group. A longitudinal study of patients with Parkinson’s disease (ELEP): aims and methodology. Rev Neurol. 2006;42: 360-5.

  11. Martínez-Martín P, Hernández B, Ricart J. Factores determinantes del inicio de tratamiento con levodopa/carbidopa/entacapona en pacientes españoles con enfermedad de Parkinson. Neurología. 2013. [Epub ahead of print]

  12. Van Rooden SM, Colas F, Matínez-Martín P, et al. Clinical subtypes of Parkinson’s disease. Mov Disord. 2011;26:51-8.

  13. Dujardin K, Leentjens AF, Langlois C, et al. The spectrum of cognitive disorders in Parkinson’s disease: A data-driven approach. Mov Disord. 2013;28:183-9.

  14. Steenland K, MacNeil J, Seals R, Levey A. Factors affecting survival of patients with neurodegenerative disease. Neuroepidemiology. 2010;35:28-35.

  15. Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000;57:369-72.






>Journals >Gaceta Médica de México >Year 2013, Issue 5
 

· Journal Index 
· Links 






       
Copyright 2019